GENE ONLINE|News &
Opinion
Blog

Everest, Calliditas Win First Approval for Rare Kidney Disease Drug in Europe

by Joy Lin
Share To

Shanghai-based Everest Medicines has announced the European approval of its rare kidney drug, Kinpegyo. Approval was granted to Everest’s partner, Calliditas Therapeutics, a Swedish biopharma. Developed under the name Nefecon, the drug will be used to treat primary immunoglobulin A (IgA) in nephropathy (IgAN) in high-risk adults with urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.

Kinpegyo, an orphan medicine, is the first Europe-approved treatment for IgAN, a rare, progressive autoimmune kidney disease. 50% of patients with this condition may progress to end-stage renal disease. 

The conditional approval will cover all 27 European Union member states as well as Iceland, Norway, and Liechtenstein.

Related article: Everest Medicines Secures Breast Cancer Drug Approval in China

 

Current and Pending Approvals for Kinpegyo (Nefecon

 

The European approval is based on data from the first part of Everest and Calliditas’ pivotal Phase 3 study, NeflgArd. The trial assessed a 16mg, once daily oral dose of Kinpegyo versus placebo in adult primary IgAN patients, and met its primary endpoint in reducing UPCR levels after 9 months of treatment. 

Last December, Nefecon was granted FDA accelerated approval under the brand name Tarpeyo. More recently this April, Everest reported that the drug reduced UPCR and stabilized the eGFR in a Chinese subpopulation in line with the pivotal trial results. The new data will be included in a planned filing for approval of the drug in China in the second half of this year. 

Everest is also pursuing development and commercialization of Nefecon in Singapore and South Korea, where besides kthe Greater China region, it has exclusive rights.  

“Primary IgAN is more common in Asia than elsewhere in the world with even higher unmet demand for innovative treatment and we hope to make this important therapy available in our region soon,” commented Kerry Blanchard, MD, PhD, CEO of Everest Medicines.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Orchard Therapeutics’ Gene Therapy for Rare Neurological Disorder Wins FDA Approval
2024-03-20
Neomorph Links Together With Novo Nordisk in a $1.46 Billion Molecular Glue Partnership Deal
2024-02-27
Amicus Therapeutics Secures $430 Million Financing Pact with Blackstone to Propel Rare Disease Mission
2023-10-04
LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top